drugset / Trial / NCT03860597

Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia

NCT03860597

Phase 4 Completed 42 enrolled University of California, San Diego
RandomizedCrossoverDouble-blindSupportive care

Summary

This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory processing fidelity (APF) and auditory learning.

Timeline

Start
2018-04-01
Primary completion
2021-03-31
Completion
2021-03-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Memantine Unknown 20 mg Oral